




MAY 2022

Does early treatment with highly effective DMT improve prognosis for people with MS?

Welcome to the May 22 DELIVER-MS newsletter. We were delighted to see a first screening from Claire Rice in Bristol UK this month. We certainly need help from our new UK sites to bolster recruitment as the USA creep even further ahead. We continue to appeal to those sites who have not yet reached their recruitment target to keep entering 1-2 participants per month to the trial.

TOTAL ENROLMENT



MONTHLY ENROLLMENT AS OF 16TH MAY

2+ participants

- Cardiff (3)
- Mayo (2)
- Nottingham (2)
- Rochester (3)


1 participant


- Bristol
- Buffalo
- Cleveland
- Ohio Health
- Wisconsin


0 participants


Can you recruit 1 or 2 next month?

DELIVER-MS RACIAL REPRESENTATION

 Saran Planchon analysed data on the racial background of participants in DELIVER-MS in preparation for ECTRIMS 22. Headline findings are that overall, trial participants appear broadly representative of race according to expected population demographics (figure a & b). However, people from non-white racial backgrounds appear to be over represented within the small sample of participants who have failed screening, withdrawn from the trial or become lost to follow-up (figure c - e).



 We presented these findings at our recent Patient Advisory Committee and discussed further exploring reasons for the screen fails/ withdrawals/ losses to follow up in minority groups, to better understand how we can address these apparent inequalities. We would be grateful for your thoughts and suggestions on this data



FINAL THOUGHTS:

We continue to be hugely grateful for your efforts as we inch closer to our enrolment target of 800. Our exploration of racial inclusivity in clinical trial processes demonstrates that the data you are helping to collect will have huge value in addressing issues that are even wider than DMT alone.
